Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The company is aiming to concentrate on the clinical advancement of THC:CBD (Tetrahydrocannabinol), a partial agonist of the CB1 receptor with Cannabidiol. Both controlled substances will undergo evaluation for the treatment of chemotherapy-induced neuropathic pain.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Neurology Product Name: THC:CBD
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: German Pain Association
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 23, 2024